<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060189</url>
  </required_header>
  <id_info>
    <org_study_id>UTI Pilot Study</org_study_id>
    <nct_id>NCT01060189</nct_id>
  </id_info>
  <brief_title>Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery</brief_title>
  <official_title>Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery With Cardiopulmonary Bypass: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antifibrinolytic drugs are used to decrease perioperative bleeding and allogeneic
      transfusions. The extensively studied antifibrinolytic drug aprotinin is efficacious but
      expensive, and has been proved to link to higher risks of serious side effects including
      renal problems, myocardial events, and strokes in patients undergoing CABG. After the
      secession of aprotinin in 2007, a marked increase of blood loss and transfusions in cardiac
      surgery took place. An effective and secure hemostatic agent is badly needed. Ulinastatin,
      urinary trypsin inhibitor(UTI), is a secreted Kunitz-type protease inhibitor with a wide
      inhibition spectrum, including plasmin. Limited studies offered clues to its antifibrinolytic
      effect. Tranexamic acid has been applied for years with convinced efficacy and safety. The
      objective of the study is to evaluate the hemostatic effect of ulinastatin and tranexamic
      acid in cardiac surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2008</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative blood loss</measure>
    <time_frame>Postoperatively</time_frame>
    <description>Defined as the total volume of chest drainage postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of reexploration for bleeding</measure>
    <time_frame>Postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major bleeding</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Major bleeding is defined according to the CURE study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of allogeneic erythrocytes</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Rate of exposure and volume of allogeneic erythrocytes transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of fresh frozen plasma (FFP)</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Rate of exposure and volume of FFP transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of allogeneic platelets</measure>
    <time_frame>Perioperatively</time_frame>
    <description>Rate of exposure and volume of allogeneic platelets transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital postoperatively</measure>
    <time_frame>Postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">426</enrollment>
  <condition>Hemostasis</condition>
  <arm_group>
    <arm_group_label>Ulinastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50ml saline solution before skin incision; 50ml saline solution after neutralization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulinastatin</intervention_name>
    <arm_group_label>Ulinastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atrial or ventricular septum defect patients requiring cardiac surgery with CPB

          -  Rheumatic or recessive valvular patients requiring valvular repair or replacement with
             CPB

          -  Coronary artery disease patients requiring coronary revascularization surgery with CPB

        Exclusion Criteria:

          -  Non-primary cardiac surgery

          -  Definite liver or renal dysfunction

          -  Disorder in coagulation function

          -  Allergy

          -  Pregnancy or lactation

          -  Disabled in spirit or law

          -  Fatal conditions such as tumour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihuan Li, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jia Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fuwai Hospital, CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>February 2, 2019</last_update_submitted>
  <last_update_submitted_qc>February 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>SHI Jia</investigator_full_name>
    <investigator_title>Associated Professor and Vice Chair of department of anesthesiology, Fuwai Hospital, NCCD, PUMC &amp; CAMS</investigator_title>
  </responsible_party>
  <keyword>ulinastatin</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>cardiac surgery procedures</keyword>
  <keyword>hemostasis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

